X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma
Phase 1 Study of X-PACT (X-ray Psoralen Activated Cancer Therapy) for Intra-tumoral Injection of Superficial Tumors in Patients With Advanced Head and Neck Cancer, Breast Cancer, Soft Tissue Sarcoma or Melanoma
Sponsor: Immunolight, LLC
Listed as NCT04389281, this PHASE1 trial focuses on Advanced Solid Tumor Cancer and remains actively recruiting participants. Sponsored by Immunolight, LLC, it has been updated 14 times since 2021, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
14 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE1
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE1
-
Sep 2025 — Jan 2026 [monthly]
Recruiting PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Recruiting PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1
▶ Show 9 earlier versions
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1
-
Mar 2024 — Jul 2024 [monthly]
Recruiting PHASE1
-
Jul 2023 — Mar 2024 [monthly]
Recruiting PHASE1
-
Sep 2022 — Jul 2023 [monthly]
Recruiting PHASE1
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE1
-
Jan 2022 — Jul 2022 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Oct 2021 — Jan 2022 [monthly]
Not Yet Recruiting PHASE1
-
Jan 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE1
-
Jun 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Immunolight, LLC
For direct contact, visit the study record on ClinicalTrials.gov .